Table 1.
Clinical Trials Evaluating VEGF-targeted Therapies With Data Available in Squamous NSCLC
| Trial | Patient population | Regimen | RR | PFS | OS | Fatal hemorrhagic events |
|---|---|---|---|---|---|---|
| Johnson et al [50] | Advanced or recurrent NSCLC (N = 99); 20% squamous histology | Bevacizumab 15 mg/kg + carboplatin/paclitaxel vs carboplatin/paclitaxel alone | 31.5% vs 18.8% (overall) | TTP: 7.4 vs 4.2 mo; P = 0.023 (overall) | 17.7 vs 14.9 mo; P = 0.63 (overall) | Bevacizumab arm, n = 4 |
| BRIDGE [55] | Squamous NSCLC (N = 31) | Bevacizumab 15 mg/kg | NR | 6.2 mo (overall) | NR | N/A |
| SWOG-S0533 pilot study [56] | Unresectable advanced NSCLC (N = 29); 41% squamous histology | Bevacizumab 15 mg/kg + docetaxel 75 mg/m2 | NR | NR | 23 mo (nonsquamous) 17 mo (squamous) |
Bevacizumab arm, n = 2 (squamous, n = 2) |
| Socinski et al [57] | Stage III NSCLC (N = 45); 27% squamous histology | Induction carboplatin/paclitaxel + bevacizumab 15 mg/kg followed by concurrent carboplatin/paclitaxel + bevacizumab 10 mg/kg + TCRT (with or without erlotinib) | 60% (overall) | 10.2 mo (overall) 10 mo (squamous) |
18.4 mo (overall) 17.1 mo (squamous) |
N/Aa |
|
| ||||||
|
Sunitinib
| ||||||
| Socinski et al [60] | Chemotherapy-pretreated, advanced NSCLC (N = 63); 22% squamous histology | Sunitinib 50 mg/day | 11.1% (overall); squamous, n = 1 | 12.0 wk (overall) | 23.4 wk (overall) | Sunitinib arm, n = 3 (squamous, n = 2) |
| Scagliotti et al [65] | Chemotherapy-pretreated advanced refractory NSCLC (N = 960); sunitinib arm, 28% squamous histology | Sunitinib 37.5 mg/day + erlotinib 150 mg/day vs placebo + erlotinib 150 mg/day | 10.6% vs 6.9% (overall) | 3.6 vs 2.0 mo; P = 0.0023 (overall) | 9.0 vs 8.5 mo; P = 0.1388 (overall) | Sunitinib arm, n = 1 (hemoptysis) |
| Heist et al [63] | Chemotherapy-pretreated advanced NSCLC (N = 128); sunitinib arms, 15% squamous histology each | Sunitinib 37.5 mg/day vs pemetrexed 500 mg/m2 vs sunitinib 37.5 mg/day + pemetrexed 500 mg/m2 | NR | 3.3 vs 4.4 vs 3.7 mo; P = 0.3 (overall) | 7.0 vs 10.5 vs 6.7 mo; P = 0.0179 (overall) | N/A |
|
| ||||||
|
Sorafenib
| ||||||
| ESCAPE [61] | Untreated advanced NSCLC (N = 926); sorafenib arm, 23% squamous histology | Sorafenib 400 mg bid + carboplatin/paclitaxel vs carboplatin/paclitaxel alone | 27.4% vs 24.0% (overall) | 4.6 vs 5.4 mo (overall) 4.3 vs 5.8 mo (squamous) |
10.7 vs 10.6 mo (overall) 8.9 vs 13.6 mo (squamous) |
Sorafenib arm, n = 4 (squamous, n = 2) |
|
| ||||||
| Vadimezan | ||||||
|
| ||||||
| Lara et al [66] | Previously untreated advanced NSCLC (N = 1,299); 20% squamous histology | Vadimezan 1,800 mg/m2 + carboplatin/paclitaxel vs placebo + carboplatin/paclitaxel | 24.7% vs 24.6% (overall) | 5.5 vs 5.5 mo (overall) | 13.4 vs 12.7 mo (overall) | N/A |
VEGF, vascular endothelial growth factor; NSCLC, non-small cell lung cancer; RR, response rate; PFS, progression-free survival; OS, overall survival; TTP, time to progression; NR, not reported; N/A; not applicable; TCRT, thoracic conformal radiation therapy.
a
Two cases of delayed grade 5 pulmonary hemorrhage were observed in patients with squamous histology 53 and 151 days following TCRT.